ストックスクリーナーアプリを入手
3.82
0.93%
-0.03
前日終値:
$3.85
開ける：
$3.81
24時間の取引高:
7,343
Relative Volume:
0.09
時価総額：
$42.06M
収益：
-
当期純損益:
$-19.09M
株価収益率:
-2.1461
EPS:
-1.78
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
+1.71%
1か月 パフォーマンス:
-5.82%
6か月 パフォーマンス:
-0.67%
1年 パフォーマンス:
-61.97%
1日の値動き範囲:
$3.80
$3.9986
1週間の範囲:
$3.58
$4.0099
52週間の値動き範囲:
$2.79
$10.47
Lantern Pharma Inc Stock (LTRN) Company Profile
LTRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.882 | 42.06M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.93 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.88 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.45 | 35.74B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
272.55 | 35.58B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.24 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-07 | 開始されました | H.C. Wainwright | Buy |
Lantern Pharma Inc (LTRN) 最新ニュース
Lantern Pharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace
Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - StockTitan
LTRN: M&A Illuminates GBM Value - Yahoo Finance
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World
Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech - Insider Monkey
Lantern Pharma advances AI-driven drug development with patent - Investing.com India
Lantern Pharma advances AI-driven drug development with patent By Investing.com - Investing.com Nigeria
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire
Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance
Top 10 AI Stocks Dominating Wall Street - Insider Monkey
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey
Lantern Pharma Extends CSO’s Employment Agreement - TipRanks
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 13.3% – What’s Next? - Defense World
Oncology Drugs Fast-Tracked by the FDA in December 2024 - Oncology News Central
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance
15 AI News Updates That Broke The Internet - Insider Monkey
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com
LP-184 gains FDA fast track for triple negative breast cancer - Investing.com
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune
Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire
10 Best AI Penny Stocks Under $10 in 2024 - CoinCodex
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace
Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com
Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate, Expands to Japan Trial | LTRN Stock News - StockTitan
32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.
III: TechBio News Day 👾 - substack.com
LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance
Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com
Lantern Pharma Inc (LTRN) 財務データ
収益
当期純利益
現金流量
EPS
Lantern Pharma Inc (LTRN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
1.66%
4.32%
大文字化:
|
ボリューム (24 時間):